August 5, 2026Clinical Cancer ResearchPOD1UM-303 / POD1UM-202 (NCT04472429; NCT03597295)
FDA Approves Retifanlimab, First Checkpoint Inhibitor for Anal Squamous Cell Carcinoma
The FDA approved retifanlimab, a PD-1-targeting checkpoint inhibitor, in combination with carboplatin and paclitaxel for first-line treatment and as a single agent for second-line treatment of squamous cell carcinoma of the anal canal (SCAC) — the first checkpoint inhibitor approval in this disease.